Liquidia Corporation

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

lqda

Cash and Cash Equivalents

Last Annual Value

190.68M

3-Year CAGR

27%

5-Year CAGR

24%

10-Year CAGR

63%

Liquidia Corporation

Liquidia Corporation Competitors Analysis of Cash and Cash Equivalents

LQDA · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
190.68M
31.6%27.1%63.0% 
312.01M
80.3%7.3%22.4%
799.62M
83.3%50.0%N/A
205.33M
17.3%-6.9%17.8%
ETNB logo
89bio, Inc.
NASDAQ:ETNB
126.06M
-26.4%19.2%N/A
88.33M
-30.7%-13.4%27.0%
222.00M
20.5%8.5%13.0%
737.06M
55.6%35.0%36.5%
89.13M
0.3%-15.2%-17.0%
Liquidia Corporation

Liquidia Corporation Fair Value Envelope

LQDA · NASDAQ

Our analysis suggests that LQDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $55.69, this represents a potential HIDDEN relative to our calculated worth for Liquidia Corporation.

Intrinsic Value
Current Price: $55.69